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Abstract 
Background: Risk prediction of ventricular arrhythmias after myocardial infarction (MI) is 
still insufficient. Prolonged QTc is a known risk marker of mortality and ventricular 
arrhythmias. QTc has not achieved clinical importance in predicting arrhythmic events in 
patients after MI. Recent studies have displayed that the terminal part of the QT-interval, T-
peak to T-end (TpTe) may be a more promising predictor of adverse outcome. Herein, we 
assessed whether TpTe may serve as a predictor of ventricular arrhythmias in patients with 
previous MI fulfilling current ICD indications. 
Methods: Seventy-six patients with previous MI eligible for ICD therapy were prospectively 
enrolled. ECG measurements at baseline were recorded using a 12 lead ECG with 50 mm/s 
paper speed. TpTe was measured from peak of the T wave to end of T wave. Events during 
follow up were defined as ventricular arrhythmias requiring appropriate ICD therapy, 
including anti tachycardia pacing and shock. 
Results: During 23 ± 19 months, arrhythmic events occurred in 36 (47 %) patients. TpTe was 
longer in ICD patients with recorded ventricular arrhythmias compared with those without 
(116±26 ms vs. 102±20 ms, p=0.01), while EF at baseline did not differ (35±9 % vs. 35±11 
%, p=0.87). TpTe was an independent predictor of ventricular arrhythmias when adjusted for 
age, EF and QRS duration (HR 1.16; 95% CI 1.03-1.31, p=0.02). 
Conclusions: TpTe predicted malignant arrhythmias in patients after MI independently of EF. 
TpTe may contribute in the risk stratification of patients to identify post-MI patients disposed 
to malignant arrhythmias and their need of ICD-therapy. 
Key words: ECG, ventricular arrhythmias, myocardial infarction 
  
Abbreviations: 
TpTe = T-peak to T-end 
 MI = myocardial infarction 
ICD = implantable cardioverter-defibrillator 
EF = ejection fraction 
VF = ventricular fibrillation 
VT = ventricular tachycardia 
LV = left ventricular 
ROC = receiver-operating characteristic 
AUC = area under the curve 
 
 
 
  
 Ventricular arrhythmias are the major cause of sudden cardiac death in patients after 
myocardial infarction (MI). Despite improved treatment of patients with MI by coronary 
revascularization, a substantial proportion of patients still suffer from sudden cardiac death. 
ICD therapy is the leading therapy available to avert sudden death in high-risk patients 
1-3
. 
However, ICD is not an inert therapy and carries risk of complications. Therefore, effective 
selection of patients for this therapy is needed. Left ventricular (LV) ejection fraction (EF) is 
currently the main parameter applied to select patients for implantable cardioverter-
defibrillator (ICD) therapy 
3-5
. EF is an excellent predictor for prognosis of heart failure and 
heart failure death, but has limitations in accurate prediction of sudden death. Less than 50 % 
of patients with prior infarction, who die suddenly, have EF below 30 % 
1,6-8
. There is a 
growing awareness of the limitations of EF as the only risk stratification tool for ICD therapy 
1,5,9,10
. A variety of different parameters have been reported to improve prediction of 
ventricular arrhythmias, but no single parameter has so far shown sufficient sensitivity and 
specificity for this devastating event. A combination of several risk markers, including 
reduced EF, will most likely provide the most reliable risk stratification for sudden cardiac 
death 
1,11,12
.  
However, QTc has not achieved clinical importance in predicting arrhythmic events in 
patients after MI. Previous studies have shown that the ECG measurement of T-peak to T-end 
(TpTe) is a predictor of mortality during the first year after MI 
13-16
. TpTe is defined as the 
time interval between the peak amplitude of the T wave and the end of the T-wave. TpTe is 
suggested as an index of total spatial dispersion of cardiac repolarization
17
. Increased 
dispersion of repolarization contributes to the development of malignant ventricular 
arrhythmias and may be the mechanism of why prolonged TpTe may be a marker of increased 
risk of ventricular arrhythmias 
13,18
. We hypothesized that TpTe may be a marker of 
ventricular arrhythmias by reflecting the mechanisms of arrhythmogenesis. The purpose of 
the present study was to evaluate if TpTe can serve as an additional risk marker for the 
occurrence of malignant ventricular arrhythmias in patients with implanted ICD after MI. 
Methods 
Study population 
  A total of 76 post-MI patients fulfilling indications for ICD therapy were prospectively 
included.  Regional Committee for Medical Research Ethics approved the study. Written 
informed consent was obtained from all patients. 
The inclusion criteria were patients implanted with ICD after MI on primary or 
secondary prevention criteria according to current guidelines 
3,4,19
. Primary prevention criteria 
included patients with EF < 35% at least 40 days after MI or EF < 40% and non-sustained 
ventricular tachycardia (nsVT) and sustained arrhythmia inducible by an electrophysiology 
study. Secondary prevention criteria included patients with prior MI who had survived a 
cardiac arrest or sustained ventricular tachycardia (VT). The exclusion criteria were prior 
coronary artery bypass graft surgery, severe valvular dysfunction, atrial fibrillation and bundle 
branch block on ECG.  
All the participants underwent coronary angiography before implantation of ICD. 
Revascularization therapy and medical treatment were documented. The time from ICD 
implantation to the first arrhythmic event during follow-up was documented. Arrhythmic 
events were defined as appropriate anti-tachycardia pacing or shock from the defibrillator. 
Follow-up time after ICD implantation was a minimum of 300 days.  
TpTe measurements  
ECG measurements prior to ICD implantation were recorded using a 12 lead ECG 
with 50 mm/s paper speed. TpTe was measured using two methods. The “tail method” 
(TpTeTail) was defined as the time in milliseconds from the peak of the T-wave (Tp) (or 
nadir if the T-wave was negative or biphasic) to the point where the T-wave returns to the iso 
electric line (end of the T-wave, Te) 
13,20
 (Figure 1). The “tangent method” (TpTeTangent) 
was defined as time from Tp (or nadir) and the intersection between the tangent at the steepest 
point of the T-wave downslide and the isoelectric line 
13,21
. In contrast to the tail method, the 
tangent method did not include the terminal phase of the T-wave. TpTe were measured from 
all 12 ECG leads and the longest TpTe was recorded. All TpTe measurements were corrected 
for heart rate using a modified Bazett’s formula, TpTeC= TpTe / square root of RR interval. 
The data described of TpTe in this paper were derived from the tail method if not contrarily 
specified. TpTeC was measured by one author blinded to the clinical outcomes. A random 
selection of ECGs was re-measured by the same observer to assess intraobserver variability. 
TpTeC was re-measured by a cardiologist blinded to the first measurements to assess 
interobserver reproducibility. QRS interval and QT interval were measured according to 
current standards and QT-interval was rate corrected (QTc) by Bazett’s formula.  
Echocardiographic examination was performed prior to the ICD implantation at the 
same day as the ECG recording. EF was assessed by the modified Simpson method.  
The use of beta blockers, ACE inhibitors and amiodarone at ICD implantation was 
recorded.  
Statistical analyses 
Data were presented as mean ± standard deviation (SD), numbers (percentages) and 
median (interquartile range). Comparisons of means were analyzed using unpaired t tests 
(SPSS version 19; SPSS, Inc., Chicago, IL). Cox regression analysis was performed to 
identify predictors of ventricular arrhythmias requiring appropriate ICD treatment. Significant 
predictors (p<0.05) from univariable analyses were included in multivariable regression 
analyses. Receiver operating characteristics (ROC) curves were utilized to determine 
specificity and sensitivity of TpTeC to detect those with ventricular arrhythmias. The value 
closest to the upper left corner of the ROC curve was defined as the cut off value for optimal 
sensitivity and specificity for TpTeC to identify arrhythmic events. Kaplan-Meier analysis 
was used to create freedom-from-arrhythmia curves. P-values were two-tailed and values 
<0.05 were considered significant.  
Results 
Mean age was 63.1 ± 9.8 years in all patients and 65 (86 %) were male. Age and 
gender were similar in patients with arrhythmic events and in those without (Table 1). Thirty-
eight were included on ICD primary prevention criteria and 38 on secondary prevention 
criteria. Time since MI was median 6 months (range 0-36 months). PCI was performed in 46 
(61 %) patients, while 30 (39 %) were considered ineligible for revascularization. 
During 23 ± 19 months of follow-up, 36 (47 %) of the 76 included ICD patients 
experienced one or more events with ventricular arrhythmias in need for ICD therapy (anti-
tachycardia pacing or shock). TpTeTailC and QRS-interval were significantly longer in ICD 
patients with arrhythmic events compared to those without arrhythmic events (p = 0.01 and 
p= 0.05, respectively) (Table 1). There was no difference in TpTeTangentC, EF, QTc and 
medications between the two groups. In multivariable Cox regression analysis, TpTeTailC 
was a strong predictor of ventricular arrhythmias during follow up and predicted arrhythmic 
events independently of age and EF (Table 2). ROC analyses identified TpTeTailC > 100 ms 
as the optimal cut off value with a sensitivity of 75 % and specificity of 48 %. AUC was 0.67 
(95% CI, 0.55-0.79). Kaplan-Meier analyses showed that patients with TpTeTailC > 100 ms 
had more frequent arrhythmic events than patients with TpTeTailC < 100 ms (p=0.05) (Figure 
2).  
There was no difference in TpTeTailC between patients with ICD on primary (111 ± 
26 ms) versus patients with ICD on secondary (106 ± 21 ms) prevention criteria (p=0.37).  
Patients with EF > 35% 
Thirty-eight patients were implanted with ICD on secondary prevention criteria and 
had EF > 35 % and were analyzed separately. Event rate of ventricular arrhythmias requiring 
appropriate ICD therapy among these patients with relatively preserved EF was 20 (53 %) 
(Table 3). TpTeTailC was prolonged in those with arrhythmic events during follow up 
compared to those without arrhythmic events. QRS-interval, QTc duration, LV volumes, EF 
and medications were similar in these two groups. Cox regression analysis in patients with EF 
> 35% showed that TpTeTailC was a significant predictor of arrhythmic events and predicted 
events independently of age and EF. ROC analyses identified a TpTeTailC of > 100 ms as the 
optimal cut off value with AUC 0.70 (95% CI 0.54-0.87) with a sensitivity of 71 % and 
specificity of 61 %. Kaplan Meier plot showed significantly better arrhythmia free survival in 
those with a TpTeTailC < 100 ms (p=0.03) (Figure 3).  
Reproducibility  
The intra observer interclass correlation coefficient for TpTe measurements was 0.95 
(95 % CI, 0.90 - 0.98) and the inter observer intraclass correlation coefficient was 0.86 (95 % 
CI, 0.73 - 0.92).  
Discussion  
This study demonstrated that TpTeTailC was a marker of risk for ventricular 
arrhythmias in patients after MI. Recent studies have shown that TpTeTailC was a marker of 
mortality in patients after MI 
13
. Importantly, TpTeTailC predicted ventricular arrhythmias 
also in those with relatively preserved ventricular function. These findings indicate that the 
specific mechanisms for occurrence of ventricular arrhythmias may be assessed by TpTeTailC 
and that it may be used as an additional risk stratification tool for ICD treatment in patients 
after MI.  
Current risk stratification for ventricular arrhythmias in patients after MI 
Selection of patients after MI for ICD therapy remains challenging. Current guidelines 
recommend primary prevention by ICD implantation when EF is < 35 % and New York Heart 
Association class is II or III 
3,22
. Nevertheless, a considerable percentage of those who die 
from ventricular arrhythmias have EF > 35 % 
22,23
 and thereby, the current guidelines fail to 
address a large number of patients. Thus, supplementary risk stratification tools are needed. 
EF is a volume based measure for LV function and is an excellent marker of contractile 
dysfunction and heart failure, but cannot predict electrophysiological dysfunction when 
contractile function is preserved. It is obvious that EF does not directly assess the 
electrophysiological substrates responsible for triggering ventricular arrhythmias 
24
. An ideal 
risk marker should provide reliable information with adequate specificity and sensitivity. 
Furthermore, a marker should also be economically affordable, safe to obtain, simple to 
interpret and easily accessible in healthcare 
24
. Currently, no single marker for predicting 
arrhythmias exists and a combination of markers seems to be the most promising approach.  
TpTeTailC as an additional risk marker of ventricular arrhythmias and 
mechanisms of prolonged TpTe interval 
We have recently demonstrated that TpTeTailC is a predictor of first year mortality in 
patients after MI and that TpTeTailC provided additional prognostic information in these 
patients compared to traditional risk factors 
13
. The study by Erikssen et al also indicated that 
TpTeTailC may be a specific predictor of sudden, probably arrhythmic, death. Importantly, 
the present study adds further to the knowledge of TpTeTailC as a prognostic marker, by 
showing more directly that TpTeTailC is a marker of ventricular arrhythmias and may reflect 
underlying electrical mechanisms for ventricular arrhythmias.  
Dispersion of ventricular repolarization has been recognized as a mechanism for 
ventricular arrhythmias and may be indicative for the patient's risk of developing arrhythmias 
even before the threshold value is reached 
25
. TpTeTailC has been correlated to transmural 
electrical heterogeneity and reflects electrical dispersion in patients with long QT syndrome 
25,26
. Furthermore, TpTeTailC has been associated with drug-induced QT interval 
prolongation and expresses total distribution of repolarization in the whole LV 
27
.  
This study shows that TpTeTailC reflect arrhythmic risk in patients after MI. It is well 
known that myocardial scars after MI give rise to malignant arrhythmias 
5,28
. Ventricular 
arrhythmias after MI can arise from the heterogeneity in the scar tissue and border zones 
which establishes areas of slow conduction. A possible mechanism has been considered to be 
reexcitation of fibers with short action potentials by adjacent fibers with longer action 
potentials 
18
. Spatial dispersion of repolarization is known to prolong the QT interval, QTc 
and the QT dispersion. However, QTc include depolarization in homogeneity and conduction 
abnormalities such as bundle branch block and is therefore unspecifically prolonged in a 
variety of conditions. TpTeTailC is a more specific marker of repolarization by including only 
the phase 3 and 4 of the action potential and may therefore more specifically assess 
mechanisms for ventricular arrhythmias.   
QT dispersion, assessed as the difference between longest and shortest QT interval in a 
12 lead ECG, was presented as a promising marker of arrhythmic risk some decades ago 
29
. 
However, difficulties in assessing end of the T-wave made reproducibility challenging and the 
QT dispersion did not gain the clinical relevance as initially expected. The challenges of 
determining the end of the T-wave remain in the TpTeTail method described in this study. 
However, the TpTeTail method does not require measurements of difference as in QT 
dispersion and excludes the differences in the QRS duration as a possible confounder in 
measures of QT dispersion.  
TpTe tail versus TpTe tangent  
TpTe measured by the tail method, was a significant multivariable predictor of 
malignant ventricular arrhythmias in patients after MI. When measured with the tangent 
method, TpTe became non-significant (p = 0.14), thereby suggesting that the tail method adds 
a greater prognostic potential than the tangent method 
13
.  
Clinical implications 
TpTeTailC is easy to obtain and an inexpensive measurement from 12 lead ECG. 
Furthermore, it is simple to interpret and is a swift examination, thereby making TpTeTailC a 
potential important supplement to EF in determining which patients to select for ICD-therapy. 
Particularly, TpTeTailC may add information in patients with EF > 35 % who contribute to a 
substantial proportion of sudden deaths, but in whom EF is inadequate for prediction of 
sudden death. 
Limitations  
The study is limited by the small sample size, but has a relatively high event rate. The 
study can be regarded as a pilot study which may be confirmed by larger prospective trials.  
Measuring the end of the T-wave may be challenging, e.g. in presence of horizontal T-
waves. Still, we found an excellent inter- and intra-observer agreement in our study. 
 
Conclusions 
TpTeTailC predicted malignant arrhythmias in patients after MI independently of EF. 
TpTeTailC was an excellent predictor of arrhythmias also in those with relatively preserved 
EF. Measurement of TpTeTailC might be a supplemental parameter to help identify patients 
after MI predisposed to malignant arrhythmias and help the selection of patients for ICD 
therapy.  
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 Table 1. Clinical characteristics in 76 patients after myocardial infarction with ICD 
 Non-arrhythmia 
N= 40 
Arrhythmia 
N= 36 
P-value 
Age (years) 61.7 ± 9.4 64.6 ± 10.2 0.21 
Female/Male (n) 8/32 (20 %) 3/33 (8 %) 0.15 
Heart Rate (bpm) 68 ± 13 63 ± 14 0.12 
QRS duration (ms) 104 ± 20 114 ± 26 0.05 
QTc (ms) 440 ± 80 450 ± 30 0.44 
TpTe-TailC (ms) 102 ± 20 116 ± 26 0.01 
TpTe-TangentC (ms) 96 ± 16 102 ± 20 0.14 
EDV (ml) 190 ± 69 195 ± 80 0.79 
ESV (ml) 126 ± 61 129 ± 65 0.84 
EF (%) 34.5 ± 11.1 34.9 ± 9.0 0.87 
Amiodarone (n) 9 (23 %) 6 (17 %) 0.50 
Beta-blocker (n) 37 (93 %) 33 (92 %) 0.58 
ACE inhibitor (n) 34 (85 %) 30 (83 %) 0.64 
Values are mean ± SD and n (%). TpTe: T-peak to T-end, EDV: End diastolic volume, ESV: 
End systolic volume, EF: Ejection fraction  
 Table 2. Predictors of ventricular arrhythmias in 76 patients after myocardial infarction with 
ICD by Cox Regression analyses. 
                                                               Univariate     Multivariate 
 HR 95 % CI P-value  HR   95 % CI P-value 
Age (years) 1.01 0.98-1.05 0.40 1.02  0.98-1.05 0.34 
QRS duration (per 10 ms increase) 1.14 1.00-1.29 0.05 1.11  0.98-1.26 0.12 
EF (%) 1.00 0.97-1.03 0.97 1.01  0.98-1.05 0.45 
TpTe-TailC (per 10 ms increase) 1.16 1.04-1.30  0.01 1.16  1.03-1.31 0.02 
EF: Ejection fraction, TpTe: T-peak to T-end, Hazard ratio, 95 % CI: 95% Confidence 
interval. 
 
 
 
 
  
Table 3. Clinical characteristics in 38 patients after myocardial infarction with ICD and with 
EF > 35 %  
 Non-arrhythmia 
N= 18 
Arrhythmia 
N= 20 
P-value 
Age (years) 63.2 ± 10.4 65.8 ± 10.5 0.46 
Female/Male (n) 2/16 (11 %) 1/19 (5 %) 0.50 
Heart Rate (bpm) 63 ± 13 60 ± 13 0.47 
QRS duration (ms) 101 ± 19 113 ± 28 0.13 
QTc (ms) 440 ± 40 440 ± 20 0.83 
TpTe-TailC (ms) 98 ± 19 111 ± 19 0.04 
TpTe-TangentC (ms) 95 ± 18 99 ± 16 0.48 
EDV (ml) 156 ± 39 161 ± 61 0.77 
ESV (ml) 85 ± 27 92 ± 37 0.51 
EF (%) 44.3 ± 8.4 41.7 ± 4.6 0.23 
Amiodarone (n) 5 (28 %) 5 (25 %) 0.85 
Beta-blocker (n) 18 (100 %) 18 (90 %) 0.18 
ACE inhibitor (n) 15 (83 %) 16 (80 %) 0.80 
Values are mean ± SD and n (%). TpTe: T-peak to T-end, EDV: End diastolic volume, ESV: 
End systolic volume, EF: Ejection fraction  
 
 
 
 
  
 
 
 
  
Table 4. Predictors of ventricular arrhythmias in 38 patients after myocardial infarction with 
ICD and EF > 35 % by Cox Regression analyses. 
                                                             Univariate        Multivariate 
 HR 95 % CI P-
value 
   HR 95 % CI P-value 
Age (years) 1.02 0.98-1.06 0.46   1.02  0.98-1.06 0.31 
QRS duration (per 10 ms increase) 1.12 0.96-1.31 0.14     
EF (%) 0.96 0.89-1.04 0.36   0.96  0.87-1.06 0.43 
TpTeTailC (per 10 ms increase) 1.41 1.07-1.85  0.02   1.43  1.08-1.89 0.01 
EF: Ejection fraction, TpTe: T-peak to T-end, HR: Hazard ratio, 95 % CI: 95% Confidence 
interval. 
  
Figure 1. TpTe measured by the tail method 
 
 
 
 
 
ECG from a patient with prolonged time from peak T-wave to end of T-wave by the tail 
method. This patient experienced ventricular arrhythmias during follow up.  The left vertical 
line representing T wave peak and the right vertical line representing T wave end. The time 
between the two lines is TpTe measured by the tail method.
Figure 2 
Kaplan Meier analyses in 76 patients after myocardial infarction with ICD 
 
 
Kaplan Meier curves showing freedom of ventricular arrhythmias in patients after 
myocardial infarction. Patients with TpTeTailC > 100 ms (green curve) had more 
arrhythmic events compared to patients TpTeTailC < 100 ms (red curve) (p=0.05) during 
23±19 months of follow up. 
  
 Figure 3 
Kaplan Meier analyses in 38 patients after myocardial infarction with ICD and with EF > 35 
%.  
 
 
Kaplan Meier analyses in 38 patients after myocardial infarction and ejection fraction > 35 %. 
Patients with TpTeTailC > 100 ms (green curve) had more arrhythmic events compared to 
patients with TpTeTailC < 100 ms (red curve) (p < 0.05) during 23 ± 19 months of follow up.   
